Why the study?
Appropriate risk stratification in acute pulmonary embolism is essential to identify patients who may benefit from reperfusion therapy.
Comprehensive risk stratification in acute PE, starting with hemodynamic assessment and incorporating clinical scores, biomarkers, and imaging, is essential for guiding reperfusion and anticoagulation therapy.
Provides no clinical data; leaves open updates to PE risk stratification guidance.
Pulmonary embolism (PE) is a common clinical entity, which most clinicians will encounter. Appropriate risk stratification of patients is key to identify those who may benefit from reperfusion therapy. The first step in risk assessment should be the identification of hemodynamic instability and, if present, urgent patient consideration for systemic thrombolytics. In the absence of shock, there is a plethora of imaging studies, biochemical markers, and clinical scores that can be used to further assess the patients' short-term mortality risk. Integrated prediction models incorporate more information toward an individualized and precise mortality prediction. Additionally, bleeding risk scores should be utilized prior to initiation of anticoagulation and/or reperfusion therapy administration. Here, we review the latest algorithms for a comprehensive risk stratification of the patient with acute PE.
No takes yet. Share an insight, caveat, or question.
Triantafyllou et al. (2021) studied Acute Pulmonary Embolism.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: